目的 探討復(fù)方風(fēng)濕寧片聯(lián)合塞來昔布膠囊治療早期膝骨關(guān)節(jié)炎的臨床療效。方法 選取2019年10月-2020年8月在鄂州市中心醫(yī)院治療的78例早期膝骨關(guān)節(jié)炎患者,將患者隨機(jī)分為對(duì)照組和治療組,每組各39例。對(duì)照組口服塞來昔布膠囊,200 mg/次,1次/d;治療組在對(duì)照組基礎(chǔ)上口服復(fù)方風(fēng)濕寧片,5片/次,4次/d。兩組患者均連續(xù)治療1個(gè)月。觀察兩組臨床療效,比較兩組膝關(guān)節(jié)液中炎癥因子水平、膝關(guān)節(jié)功能、疼痛程度和不良反應(yīng)。結(jié)果 治療后,治療組總有效率為92.31%,高于對(duì)照組總有效率74.36%,組間比較有顯著差異(P<0.05)。治療后,兩組膝關(guān)節(jié)液腫瘤壞死因子-α(TNF-α)、白細(xì)胞介素-1β(IL-1β)、基質(zhì)金屬蛋白酶-3(MMP-3)水平均顯著降低(P<0.05),且治療組膝關(guān)節(jié)液TNF-α、IL-1β、MMP-3水平低于對(duì)照組(P<0.05)。治療后,兩組Lysholm評(píng)分均升高,視覺模擬評(píng)分法(VAS)評(píng)分均降低(P<0.05),且治療組Lysholm評(píng)分高于對(duì)照組,VAS評(píng)分低于對(duì)照組(P<0.05)。治療后,治療組不良反應(yīng)發(fā)生率低于對(duì)照組(P<0.05)。結(jié)論 復(fù)方風(fēng)濕寧片聯(lián)合塞來昔布膠囊治療早期膝骨關(guān)節(jié)炎具有較好的臨床療效,能夠促進(jìn)膝關(guān)節(jié)修復(fù),減輕患者疼痛程度,可有效降低患者的膝關(guān)節(jié)液炎性因子水平,抑制炎癥反應(yīng),安全性較好。

Objective To investigate the effect of Compound Fengshining Tablets combined with Celecoxib Capsules in treatment of early knee osteoarthritis.Methods Patients (78 cases) with early knee osteoarthritis in Ezhou Central Hospital from October 2019 to August 2020 were randomly divided into control and treatment groups, and each group had 39 cases. Patients in the control group were po administered with Celecoxib Capsules, 200 mg/time, once daily. Patients in the treatment group were po administered with Compound Fengshining Tablets on the basis of the control group, 5 tablets/time, four times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the level of inflammatory factors in knee joint fluid, the knee function, degree of pain, and adverse reactions in two groups were compared.Results After treatment, the total effective rate of the treatment group was 92.31%, which was higher than 74.36% of the control group, and there was significant difference between two groups (P < 0.05). After treatment, the levels of TNF-α, IL-1β, and MMP-3 in knee joint fluid of two groups were significantly decreased (P < 0.05), and the levels of TNF-α, IL-1β, and MMP-3 in knee joint fluid of the treatment group were lower than those of the control group (P < 0.05). After treatment, the Lysholm score in two groups were increased, but the VAS score in two groups were decreased (P < 0.05). And the Lysholm score in the treatment group was higher than that in the control group, but the VAS score in the treatment group was lower than that in the control group (P < 0.05). After treatment, the incidence of adverse reactions in the treatment group was lower than that in the control group (P < 0.05).Conclusion Compound Fengshining Tablets combined with Celecoxib Capsules has clinical curative effect in treatment of early knee osteoarthritis, can promote the repair of knee joint, reduce the degree of pain, effectively reduce the level of inflammatory factors in knee joint fluid, and inhibit inflammatory reaction, with good safety.

R977